相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
Tatiana Shorstova et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Clinical perspectives of BET inhibition in ovarian cancer
Angeliki Andrikopoulou et al.
CELLULAR ONCOLOGY (2021)
Bromodomain-containing protein 4 silencing by microRNA-765 produces anti-ovarian cancer cell activity
Yong-Jun Ji et al.
Aging-US (2021)
Targeting Nrf2 may reverse the drug resistance in ovarian cancer
Danjie Li et al.
CANCER CELL INTERNATIONAL (2021)
The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models
Tiziana Servidei et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Metalloproteinases in Ovarian Cancer
Preston Carey et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Heme oxygenase 1: a novel oncogene in multiple gynecological cancers
Jia-Jing Lu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail
Linlin Lu et al.
CELL DEATH AND DIFFERENTIATION (2020)
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook et al.
CLINICAL CANCER RESEARCH (2020)
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells
Lu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition
Li-Ting Wang et al.
EMBO REPORTS (2020)
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
Tina Bagratuni et al.
EUROPEAN JOURNAL OF CANCER (2020)
Evolving population-based statistics for rare epithelial ovarian cancers
Koji Matsuo et al.
GYNECOLOGIC ONCOLOGY (2020)
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
Shariska Petersen et al.
GYNECOLOGIC ONCOLOGY (2020)
Targeting DNA Repair in Ovarian Cancer Treatment Resistance
M. W. Wong-Brown et al.
CLINICAL ONCOLOGY (2020)
MYC protein stability is negatively regulated by BRD4
Ballachanda N. Devaiah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients
Hui Zheng et al.
CANCER MEDICINE (2020)
Opposing Functions of BRD4 Isoforms in Breast Cancer
Shwu-Yuan Wu et al.
MOLECULAR CELL (2020)
Roles of the BRD4 short isoform in phase separation and active gene transcription
Xinye Han et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
Malaka Ameratunga et al.
BRITISH JOURNAL OF CANCER (2020)
The Long and the Short of BRD4: Two Tales in Breast Cancer
Sicong Zhang et al.
MOLECULAR CELL (2020)
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors
Poupak Fallahi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine Fuh et al.
GYNECOLOGIC ONCOLOGY (2020)
The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma
Tyler Maser et al.
CANCER MEDICINE (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer
Alison M. Kurimchak et al.
MOLECULAR CANCER RESEARCH (2019)
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
Wenqing Luan et al.
ONCOTARGETS AND THERAPY (2019)
Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis
Artur Nieszporek et al.
ACTA BIOCHIMICA POLONICA (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Alejandro Villar-Prados et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer
Ying Xu et al.
EXPERIMENTAL CELL RESEARCH (2018)
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition
Guillaume P. Andrieu et al.
MOLECULAR CANCER RESEARCH (2018)
BRD4 facilitates replication stress-induced DNA damage response
Jingwen Zhang et al.
ONCOGENE (2018)
Coactivator condensation at super-enhancers links phase separation and gene control
Benjamin R. Sabari et al.
SCIENCE (2018)
Chromatin conformation regulates the coordination between DNA replication and transcription
Ricardo Almeida et al.
NATURE COMMUNICATIONS (2018)
DNA damage repair in ovarian cancer: unlocking the heterogeneity
Mary Ellen Gee et al.
JOURNAL OF OVARIAN RESEARCH (2018)
Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
Karin Bauer et al.
Oncotarget (2018)
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
Xiangyi Li et al.
CELL REPORTS (2018)
Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells
Majid Momeny et al.
ANTI-CANCER DRUGS (2018)
The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity
Ai Liu et al.
CELL AND TISSUE RESEARCH (2018)
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
Garrett W. Rhyasen et al.
PLOS ONE (2018)
Targeting Brd4 for cancer therapy: inhibitors and degraders
Yingchao Duan et al.
MEDCHEMCOMM (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells
Z. Zhao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
D. Morel et al.
ANNALS OF ONCOLOGY (2017)
Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Aiste McCormick et al.
CLINICAL CANCER RESEARCH (2017)
Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival
Hye-yon Cho et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev et al.
CELL REPORTS (2017)
Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer
Bo Zhou et al.
FRONTIERS OF MEDICINE (2017)
Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
Ying Jing et al.
ONCOTARGET (2016)
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yuhki Yokoyama et al.
CANCER RESEARCH (2016)
BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
Ballachanda N. Devaiah et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets
Shuhui Chen et al.
ONCOLOGY LETTERS (2016)
BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
Ballachanda N. Devaiah et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhenfeng Zhang et al.
THERANOSTICS (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets
David W. Clark et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma
Oumou Goundiam et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer
Haifeng Qiu et al.
ONCOTARGET (2015)
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
Maria Giuseppina Baratta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival
Duygu Ucar et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future
Maise Al Bakir et al.
BRITISH MEDICAL BULLETIN (2014)
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Sunila Pradeep et al.
CANCER CELL (2014)
A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19
Chang Ohk Sung et al.
GYNECOLOGIC ONCOLOGY (2014)
Roles of Chk1 in cell biology and cancer therapy
Youwei Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Histone Cross-talk Connects Protein Phosphatase 1 α (PP1 α) and Histone Deacetylase (HDAC) Pathways to Regulate the Functional Transition of Bromodomain-containing 4 (BRD4) for Inducible Gene Expression
Xiangming Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Bromodomain and Extraterminal Proteins Suppress NF-E2-Related Factor 2-Mediated Antioxidant Gene Expression
Charalambos Michaeloudes et al.
JOURNAL OF IMMUNOLOGY (2014)
Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining
Andre Stanlie et al.
MOLECULAR CELL (2014)
ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling
Erhong Meng et al.
PLOS ONE (2014)
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response
M. Hussong et al.
CELL DEATH & DISEASE (2014)
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
Jessica E. Bolden et al.
CELL REPORTS (2014)
Transformation Resistance in a Premature Aging Disorder Identifies a Tumor-Protective Function of BRD4
Patricia Fernandez et al.
CELL REPORTS (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Regulation of Transcription through Acetylation of H3K122 on the Lateral Surface of the Histone Octamer
Philipp Tropberger et al.
CELL (2013)
Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells
Nidhi Gupta et al.
GYNECOLOGIC ONCOLOGY (2013)
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Chiara Gorrini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Scott R. Floyd et al.
NATURE (2013)
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello et al.
NATURE GENETICS (2013)
Brd4 Shields Chromatin from ATM Kinase Signaling Storms
Serah Choi et al.
SCIENCE SIGNALING (2013)
Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-order Chromatin Structure
Ranran Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain
Ballachanda N. Devaiah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation
Sergei Nechaev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
Deletion of the Proline-Rich Region of the Murine Metastasis Susceptibility Gene Brd4 Promotes Epithelial-to-Mesenchymal Transition- and Stem Cell-Like Conversion
Jude Alsarraj et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation
Rui Zhao et al.
NATURE CELL BIOLOGY (2011)
Ovarian Cancer Development and Metastasis
Ernst Langyel
AMERICAN JOURNAL OF PATHOLOGY (2010)
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng et al.
CANCER CELL (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Genomic instability - an evolving hallmark of cancer
Simona Negrini et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
Anup Dey et al.
MOLECULAR BIOLOGY OF THE CELL (2009)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
Bromodomain 4 activation predicts breast cancer survival
Nigel P. S. Crawford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Brd4 recruits P-TER to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression
Zhiyuan Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
RNA polymerase is poised for activation across the genome
Ginger W. Muse et al.
NATURE GENETICS (2007)
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Dwayne A. Bisgrovet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Structure and acetyl-lysine recognition of the bromodomain
S. Mujtaba et al.
ONCOGENE (2007)
Mechanisms of transcoelomic metastasis in ovarian cancer
David S. P. Tan et al.
LANCET ONCOLOGY (2006)
Notch3 gene amplification in ovarian cancer
Joon T. Park et al.
CANCER RESEARCH (2006)
Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: Preservation of acetylated chromatin
A Nishiyama et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
T Pal et al.
CANCER (2005)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein brd4
ZY Yang et al.
MOLECULAR CELL (2005)
Snail, slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
S Elloul et al.
CANCER (2005)
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
A Dey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A bromodomain protein, MCAP, associates with mitotic chromosomes and effects, G2-to-M transition
A Dey et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
